Posted inNews and Updates
Jaypirca Combo Shows Promise in Phase III CLL Trial
New Phase III trial data shows promise for Jaypirca in combination therapy for patients with relapsed/refractory Chronic Lymphocytic Leukemia (CLL).
Posted inNews and Updates
FDA Approves Belzutifan-Pembrolizumab for Kidney Cancer
The FDA has approved the belzutifan-pembrolizumab combination to treat high-risk renal cell carcinoma. Learn how this dual therapy aims to prevent recurrence.
Posted inNews and Updates
Traws Pharma Faces Setback as UK Regulator Delays Flu Trial
Traws Pharma shares dip after the MHRA delays a key influenza clinical trial, demanding additional data. Learn about the impact on the drug pipeline.
Posted inNews and Updates
New PRMT5 Inhibitor IDE892 Enters Phase 1/2 Cancer Trials
IDEAYA Biosciences has launched a Phase 1/2 trial for IDE892, a targeted PRMT5 inhibitor for MTAP-deleted lung and pancreatic cancers. Learn the latest.
Posted inNews and Updates
Traws Pharma Shares Slide Following UK Flu Trial Delay
Traws Pharma stock drops after the UK regulator delays a planned flu trial. Discover the impact of the MHRA's decision on the company's clinical pipeline.
Posted inNews and Updates
Traws Pharma Shares Slide Following UK Flu Trial Delay
Traws Pharma shares fall after UK regulators pause a planned flu drug trial. Get the latest details on the delay and what it means for the company's future.
Posted inNews and Updates
Traws Pharma Flu Drug Trial Delayed by UK Regulators
Traws Pharma shares fall as UK regulators delay a key influenza drug trial. Learn about the impact of the MHRA's decision on the company's clinical pipeline.
Posted inNews and Updates
China Overhauls Clinical Trial Guidelines to Boost Biotech
China's NMPA has updated clinical trial guidelines to accelerate drug innovation, improve research efficiency, and align with global regulatory standards.
Posted inNews and Updates
Breakthrough Stroke Treatment Gains Global Recognition
A breakthrough WA-developed stroke therapy is gaining global recognition. Learn how this innovation in neuroplasticity is improving recovery outcomes.
Posted inNews and Updates
EMA June 2026 Meeting: Key Regulatory Updates Explained
The EMA’s June 2026 board meeting focuses on critical medicine supplies, digital health integration, and streamlined regulatory pathways for new therapies.